pharmaceutical investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
pharmaceutical investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
Nine Mile Metals Announces Phase 1 Bulk Sample Update at Nine Mile Brook High Grade Lens of 13.71% CuEq over 15.10m
